[go: up one dir, main page]

AR079641A1 - Compuestos para el diagnostico por imagenes de la muerte de las celulas por apotosis - Google Patents

Compuestos para el diagnostico por imagenes de la muerte de las celulas por apotosis

Info

Publication number
AR079641A1
AR079641A1 ARP100104707A ARP100104707A AR079641A1 AR 079641 A1 AR079641 A1 AR 079641A1 AR P100104707 A ARP100104707 A AR P100104707A AR P100104707 A ARP100104707 A AR P100104707A AR 079641 A1 AR079641 A1 AR 079641A1
Authority
AR
Argentina
Prior art keywords
defines
connects
point
cyclam
group
Prior art date
Application number
ARP100104707A
Other languages
English (en)
Inventor
Andre Muller
Sabine Zitzmann-Kolbe
Niels Bohnke
Purnama Dewi-Wulfing
Doerte Oltmanns
Michael Eisenhut
Ulrike Bauder-Wuest
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42091520&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR079641(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of AR079641A1 publication Critical patent/AR079641A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Cell Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Método para realizar la deteccion por medio de FACS, por microscopia de fluorescencia o mediante el diagnostico por imágenes por PET del progreso o la regresion de un tumor en un paciente después de un tratamiento. Composiciones farmacéuticas que comprenden estos compuestos, precursores apropiados para obtenerlos, métodos para elaborarlos y conjuntos de elementos para realizar la deteccion y el diagnostico por imágenes de la muerte de las células por apoptosis. Reivindicacion 1: Un compuesto de la formula general (1) caracterizado porque a) T2 es (CH2) r18F y r = 1-6 o b) T2 es (CH2)r19F y r = 1-6 donde A es un cicleno de formula (2) o un ciclamo de formula (3) y donde ** define el punto donde se conecta con L; L es una unidad ligando unida a uno de los átomos de nitrogeno del anillo cicleno o un ciclamo y se selecciona entre el grupo de: union, (4) donde k = 1-5, (5) donde m = 1-5, (6) donde n = 1-5 y o = 2-5, y (7) donde p = 1-3 y q = 2-3 donde * define el punto donde se conecta con un átomo de nitrogeno del cicleno o el ciclamo y define el punto donde se conecta con T1, T1 es un marcador fluorescente que se selecciona entre el grupo de: (8) y (9) donde D se selecciona entre el grupo de * ' C=O (carbonilo) y * ' C(S)NH (aminocarbotioílo); E es hidrogeno; B1 es O; B2 es hidroxi; * ' define el punto donde se conecta con L; ' define el punto donde se conecta con T2; y que abarca a los isomeros, tautomeros, diastereomeros, enantiomeros, unicos, mezclas de los mismos, y sales apropiadas de los mismos.
ARP100104707A 2009-12-10 2010-12-17 Compuestos para el diagnostico por imagenes de la muerte de las celulas por apotosis AR079641A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP09075546A EP2332995A1 (en) 2009-12-10 2009-12-10 Neutralizing prolactin receptor antibodies and their therapeutic use

Publications (1)

Publication Number Publication Date
AR079641A1 true AR079641A1 (es) 2012-02-08

Family

ID=42091520

Family Applications (6)

Application Number Title Priority Date Filing Date
ARP100104564A AR079349A1 (es) 2009-12-10 2010-12-10 Anticuerpos neutralizadores contra el receptor de prolactina y su uso terapeutico
ARP100104567A AR079352A1 (es) 2009-12-10 2010-12-10 Anticuerpos neutralizadores contra el receptor de prolactina y su uso terapeutico
ARP100104563A AR079348A1 (es) 2009-12-10 2010-12-10 Anticuerpos neutralizadores contra el receptor de prolactina y su uso terapeutico
ARP100104566A AR079351A1 (es) 2009-12-10 2010-12-10 Anticuerpos neutralizadores contra el receptor de prolactina y su uso terapeutico
ARP100104565A AR079350A1 (es) 2009-12-10 2010-12-10 Anticuerpos neutralizadores contra el receptor de prolactina y su uso terapeutico
ARP100104707A AR079641A1 (es) 2009-12-10 2010-12-17 Compuestos para el diagnostico por imagenes de la muerte de las celulas por apotosis

Family Applications Before (5)

Application Number Title Priority Date Filing Date
ARP100104564A AR079349A1 (es) 2009-12-10 2010-12-10 Anticuerpos neutralizadores contra el receptor de prolactina y su uso terapeutico
ARP100104567A AR079352A1 (es) 2009-12-10 2010-12-10 Anticuerpos neutralizadores contra el receptor de prolactina y su uso terapeutico
ARP100104563A AR079348A1 (es) 2009-12-10 2010-12-10 Anticuerpos neutralizadores contra el receptor de prolactina y su uso terapeutico
ARP100104566A AR079351A1 (es) 2009-12-10 2010-12-10 Anticuerpos neutralizadores contra el receptor de prolactina y su uso terapeutico
ARP100104565A AR079350A1 (es) 2009-12-10 2010-12-10 Anticuerpos neutralizadores contra el receptor de prolactina y su uso terapeutico

Country Status (40)

Country Link
US (6) US9241989B2 (es)
EP (13) EP2332995A1 (es)
JP (7) JP2013513361A (es)
KR (2) KR101790366B1 (es)
CN (6) CN102858804A (es)
AP (1) AP2012006343A0 (es)
AR (6) AR079349A1 (es)
AU (2) AU2010330165B2 (es)
BR (2) BR112012014048B1 (es)
CA (6) CA2783514A1 (es)
CL (2) CL2012001540A1 (es)
CR (2) CR20120312A (es)
CU (2) CU20120092A7 (es)
CY (2) CY1118209T1 (es)
DK (2) DK2510002T3 (es)
DO (2) DOP2012000159A (es)
EA (2) EA028678B1 (es)
EC (2) ECSP12011966A (es)
ES (2) ES2603352T3 (es)
GT (1) GT201200186A (es)
HR (2) HRP20161401T1 (es)
HU (2) HUE030143T2 (es)
IL (2) IL220149A (es)
IN (2) IN2012DN05082A (es)
LT (2) LT2510006T (es)
MA (1) MA33888B1 (es)
ME (1) ME02577B (es)
MX (2) MX339343B (es)
NZ (2) NZ600511A (es)
PE (3) PE20171134A1 (es)
PH (2) PH12012501129A1 (es)
PL (2) PL2510006T3 (es)
PT (2) PT2510006T (es)
RS (2) RS55277B1 (es)
SG (2) SG181511A1 (es)
SI (2) SI2510002T1 (es)
TN (1) TN2012000294A1 (es)
TW (5) TWI508744B (es)
WO (6) WO2011069795A1 (es)
ZA (2) ZA201204214B (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2332995A1 (en) * 2009-12-10 2011-06-15 Bayer Schering Pharma Aktiengesellschaft Neutralizing prolactin receptor antibodies and their therapeutic use
ES2765418T3 (es) 2010-03-01 2020-06-09 Bayer Healthcare Llc Anticuerpos monoclonales optimizados contra el inhibidor de la ruta del factor tisular (TFPI)
EP2530089A1 (en) 2011-06-03 2012-12-05 Bayer Pharma Aktiengesellschaft Neutralising prolactin receptor antibody Mat3 and its therapeutical use
EA036225B1 (ru) 2012-03-14 2020-10-15 Ридженерон Фармасьютикалз, Инк. Мультиспецифические антигенсвязывающие молекулы и их применения
US8883979B2 (en) * 2012-08-31 2014-11-11 Bayer Healthcare Llc Anti-prolactin receptor antibody formulations
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
RS57259B1 (sr) 2012-12-24 2018-08-31 Abbvie Inc Prolaktin receptor vezujući proteini i njihova upotreba
US20160002342A1 (en) * 2013-03-15 2016-01-07 Xinghang Ma Anti-prolactin receptor antibody formulations
TWI641620B (zh) 2013-08-21 2018-11-21 再生元醫藥公司 抗－ｐｒｌｒ抗體及其用途
US9545451B2 (en) 2013-08-21 2017-01-17 Regeneron Pharmaceuticals, Inc. Anti-PRLR antibodies and methods for killing PRLR-expressing cells
EP3139955B1 (en) 2014-04-30 2024-03-20 President and Fellows of Harvard College Fusion proteins for treating cancer and related methods
WO2016054603A2 (en) 2014-10-02 2016-04-07 City Of Hope Multivalent meditopes, meditope-binding antibodies and uses thereof
TWI703156B (zh) 2015-01-30 2020-09-01 學校法人埼玉醫科大學 抗ａｌｋ２抗體
KR20180025865A (ko) 2015-07-06 2018-03-09 리제너론 파마슈티칼스 인코포레이티드 다중특이적 항원 결합 분자 및 이의 용도
EP3448891A1 (en) 2016-04-28 2019-03-06 Regeneron Pharmaceuticals, Inc. Methods of making multispecific antigen-binding molecules
EP3548514A1 (en) 2016-11-29 2019-10-09 Regeneron Pharmaceuticals, Inc. Methods of treating prlr positive breast cancer
FR3062213B1 (fr) * 2017-01-20 2021-02-26 Endodiag Utilisation du recepteur cd71 dans la detection et le traitement de l’endometriose
TW201836647A (zh) 2017-04-06 2018-10-16 美商艾伯維有限公司 抗－ｐｒｌｒ抗體藥物軛合物（ａｄｃ）及其用途
EP3621618A4 (en) * 2017-05-12 2021-01-27 Millennium Pharmaceuticals, Inc. TREATMENT OF GASTROPARESIA USING TRIAZASPIRO (4.5) DECANONE
KR20200027494A (ko) 2017-07-10 2020-03-12 바이엘 파마 악티엔게젤샤프트 남성 및 여성 패턴 탈모를 위한 프로락틴 수용체 항체
KR20200118151A (ko) 2018-02-07 2020-10-14 리제너론 파마슈티칼스 인코포레이티드 치료 단백질 전달을 위한 방법 및 조성물
WO2019169330A1 (en) * 2018-03-02 2019-09-06 Oncolix, Inc. Method for treating cancers expressing prolactin receptor
CN109627340B (zh) * 2018-12-05 2021-02-12 上海交通大学 Cd3和prlr双特异性抗体及其构建与应用
US10467487B1 (en) * 2018-12-11 2019-11-05 Chongqing Jinkang New Energy Automobile Co., Ltd. Fusion-based traffic light recognition for autonomous driving
CN112425568A (zh) * 2020-12-11 2021-03-02 上海市计划生育科学研究所 一种建立具有emt特征的良性前列腺增生bph犬模型的方法
AR124681A1 (es) 2021-01-20 2023-04-26 Abbvie Inc Conjugados anticuerpo-fármaco anti-egfr
CN114853890B (zh) * 2022-03-16 2023-04-28 沈阳三生制药有限责任公司 一种prlr抗原结合蛋白及其制备方法和应用
CN114634574B (zh) * 2022-04-18 2022-12-20 先进生物(苏州)有限公司 抗B7H6的scFv抗体、其编码基因及其应用
CN120842400A (zh) * 2023-04-24 2025-10-28 深圳真实生物医药科技有限公司 泌乳素受体抗体及其用途
CN117285625B (zh) * 2023-11-24 2024-01-23 南京佰抗生物科技有限公司 抗泌乳素蛋白的单克隆抗体及应用

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4657760A (en) 1979-03-20 1987-04-14 Ortho Pharmaceutical Corporation Methods and compositions using monoclonal antibody to human T cells
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4510245A (en) 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US5206344A (en) 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
US4968615A (en) 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
US4986615A (en) 1988-10-17 1991-01-22 The Vendo Company Vending apparatus
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5225212A (en) 1989-10-20 1993-07-06 Liposome Technology, Inc. Microreservoir liposome composition and method
GB9105245D0 (en) * 1991-03-12 1991-04-24 Lynxvale Ltd Binding molecules
CA2103887C (en) 1991-12-13 2005-08-30 Gary M. Studnicka Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
AU725609C (en) 1995-08-18 2002-01-03 Morphosys Ag Protein/(poly)peptide libraries
JP2001500865A (ja) * 1996-09-13 2001-01-23 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティ 避妊の非ホルモン法
GB9701425D0 (en) 1997-01-24 1997-03-12 Bioinvent Int Ab A method for in vitro molecular evolution of protein function
US6867187B2 (en) * 2000-12-22 2005-03-15 Trustees Of The University Of Pennsylvania Composition and method for modulating somatolactogenic function
EP1325930A1 (en) * 2002-01-08 2003-07-09 Institut National De La Sante Et De La Recherche Medicale (Inserm) Mammal prolactin variants
CA2509825A1 (en) * 2002-12-13 2004-07-01 The Ohio State University Antagonists for human prolactin
GB0305790D0 (en) * 2003-03-13 2003-04-16 Glaxosmithkline Biolog Sa Novel Composition
EP1810690B1 (en) * 2004-10-28 2012-01-18 Kyowa Hakko Kirin Co., Ltd. Anti-IL-5 receptor antibody for use in treating endometriosis.
WO2006089678A2 (en) * 2005-02-22 2006-08-31 Bioinvent International Ab Antibodies and peptides binding to hiv tat, and uses thereof
GB0517878D0 (en) * 2005-09-02 2005-10-12 Bioinvent Int Ab Immunotherapeutic treatment
US7422899B2 (en) 2005-10-05 2008-09-09 Biogen Idec Ma Inc. Antibodies to the human prolactin receptor
PL2059535T3 (pl) 2006-08-18 2014-04-30 Novartis Ag Przeciwciało specyficzne względem PRLR i jego zastosowanie
JP2010530215A (ja) 2007-05-30 2010-09-09 オークランド ユニサービシス リミテッド 成長ホルモンおよび関連ホルモンの阻害剤、ならびにそれらの使用方法
EP2025683A1 (en) * 2007-08-13 2009-02-18 INSERM (Institut National de la Santé et de la Recherche Medicale) Variants of prolactin as antagonists of its receptor
EP2332995A1 (en) * 2009-12-10 2011-06-15 Bayer Schering Pharma Aktiengesellschaft Neutralizing prolactin receptor antibodies and their therapeutic use
WO2011139375A1 (en) * 2010-05-06 2011-11-10 Ludwig Institute For Cancer Research Ltd Antibodies directed against carbonic anhydrase ix and methods and uses thereof
GB201020995D0 (en) * 2010-12-10 2011-01-26 Bioinvent Int Ab Biological materials and uses thereof

Also Published As

Publication number Publication date
EP2567979A1 (en) 2013-03-13
EP2510005A1 (en) 2012-10-17
HUE031631T2 (en) 2017-07-28
CN102884082B (zh) 2015-05-20
RS55589B1 (sr) 2017-06-30
CA2783514A1 (en) 2011-06-16
WO2011069797A1 (en) 2011-06-16
HRP20161401T1 (hr) 2016-12-16
PT2510006T (pt) 2017-01-20
CA2783678A1 (en) 2011-06-16
AP2012006343A0 (en) 2012-06-30
CN102858801A (zh) 2013-01-02
US20120315276A1 (en) 2012-12-13
RS55277B1 (sr) 2017-02-28
US9649374B2 (en) 2017-05-16
HRP20170016T1 (hr) 2017-02-24
KR101765968B1 (ko) 2017-08-08
SG181513A1 (en) 2012-07-30
ZA201204213B (en) 2014-08-27
TW201130506A (en) 2011-09-16
CA2783610C (en) 2018-10-30
PL2510002T3 (pl) 2017-02-28
WO2011069794A1 (en) 2011-06-16
WO2011069795A1 (en) 2011-06-16
TW201130507A (en) 2011-09-16
EP2510007A1 (en) 2012-10-17
EP2332995A1 (en) 2011-06-15
PT2510002T (pt) 2016-11-23
EP2567980A1 (en) 2013-03-13
JP2013513361A (ja) 2013-04-22
KR20120112527A (ko) 2012-10-11
KR20120112528A (ko) 2012-10-11
US20130022606A1 (en) 2013-01-24
CN102858804A (zh) 2013-01-02
CN102741291A (zh) 2012-10-17
EA028678B1 (ru) 2017-12-29
DOP2012000159A (es) 2012-09-30
TWI508744B (zh) 2015-11-21
BR112012014048B1 (pt) 2021-10-26
MA33888B1 (fr) 2013-01-02
PE20121360A1 (es) 2012-10-11
EP2570435A1 (en) 2013-03-20
IL220149A (en) 2017-09-28
EP2510002B1 (en) 2016-08-24
PE20171134A1 (es) 2017-08-09
CY1118209T1 (el) 2017-06-28
PH12012501131A1 (en) 2017-08-23
AU2010330161A1 (en) 2012-07-05
JP2013513364A (ja) 2013-04-22
BR112012015852A8 (pt) 2017-06-27
AU2010330161B2 (en) 2015-07-09
HK1180700A1 (en) 2013-10-25
CA2783513C (en) 2018-08-14
CU20120093A7 (es) 2012-10-15
HK1180354A1 (en) 2013-10-18
CY1118407T1 (el) 2017-06-28
LT2510006T (lt) 2016-12-12
SI2510006T1 (sl) 2017-02-28
AU2010330165B2 (en) 2015-07-16
DK2510002T3 (en) 2016-11-28
BR112012015852A2 (pt) 2017-05-23
AR079349A1 (es) 2012-01-18
TW201138817A (en) 2011-11-16
EP2567978A1 (en) 2013-03-13
TW201130504A (en) 2011-09-16
ZA201204214B (en) 2014-08-27
CA2783513A1 (en) 2011-06-16
WO2011069798A1 (en) 2011-06-16
IL220149A0 (en) 2012-07-31
TW201130505A (en) 2011-09-16
LT2510002T (lt) 2016-11-25
ME02577B (me) 2017-06-20
DOP2012000160A (es) 2012-09-30
EP2510006B1 (en) 2016-11-09
IN2012DN05078A (es) 2015-10-23
US20130272968A1 (en) 2013-10-17
MX2012006620A (es) 2012-06-21
EP2570436A1 (en) 2013-03-20
EA029327B1 (ru) 2018-03-30
CN102947338A (zh) 2013-02-27
DK2510006T3 (en) 2017-01-23
EP2510002A1 (en) 2012-10-17
EP2510004A1 (en) 2012-10-17
AR079348A1 (es) 2012-01-18
PL2510006T3 (pl) 2017-06-30
EP2510006A1 (en) 2012-10-17
EP2567977A1 (en) 2013-03-13
IL220151A0 (en) 2012-07-31
PE20121561A1 (es) 2012-11-25
CL2012001540A1 (es) 2013-01-18
CN102947338B (zh) 2015-11-25
HUE030143T2 (en) 2017-04-28
JP2013513365A (ja) 2013-04-22
CA2783651A1 (en) 2011-06-16
SI2510002T1 (sl) 2016-12-30
NZ600511A (en) 2014-01-31
NZ600512A (en) 2014-11-28
TN2012000294A1 (en) 2013-12-12
WO2011069795A4 (en) 2011-08-18
US20120321632A1 (en) 2012-12-20
CL2012001539A1 (es) 2012-10-12
ES2603352T3 (es) 2017-02-27
WO2011069799A1 (en) 2011-06-16
BR112012014048A2 (pt) 2017-10-31
AR079352A1 (es) 2012-01-18
TWI487536B (zh) 2015-06-11
CR20120312A (es) 2012-08-27
AR079350A1 (es) 2012-01-18
BR112012015852B8 (pt) 2021-05-25
CN102884082A (zh) 2013-01-16
SG181511A1 (en) 2012-07-30
EA201200851A1 (ru) 2013-01-30
CA2783654A1 (en) 2011-06-16
CN102858803A (zh) 2013-01-02
ECSP12011965A (es) 2012-07-31
EA201200860A1 (ru) 2013-01-30
IN2012DN05082A (es) 2015-10-09
ES2610654T3 (es) 2017-04-28
CA2783610A1 (en) 2011-06-16
US20130129739A1 (en) 2013-05-23
JP6199930B2 (ja) 2017-09-20
MX339343B (es) 2016-05-20
JP2013513362A (ja) 2013-04-22
JP2013513559A (ja) 2013-04-22
CU23973B1 (es) 2013-12-27
US20130171147A1 (en) 2013-07-04
GT201200186A (es) 2014-01-06
AU2010330165A1 (en) 2012-07-19
AR079351A1 (es) 2012-01-18
PH12012501129A1 (en) 2012-11-05
JP2013513363A (ja) 2013-04-22
MX2012006621A (es) 2012-10-05
US9241989B2 (en) 2016-01-26
BR112012015852B1 (pt) 2020-12-29
JP6066474B2 (ja) 2017-01-25
JP2015180690A (ja) 2015-10-15
KR101790366B1 (ko) 2017-10-26
WO2011069796A1 (en) 2011-06-16
CR20120310A (es) 2012-08-01
EP2510003A1 (en) 2012-10-17
ECSP12011966A (es) 2012-07-31
CU20120092A7 (es) 2012-10-15

Similar Documents

Publication Publication Date Title
AR079641A1 (es) Compuestos para el diagnostico por imagenes de la muerte de las celulas por apotosis
ECSP10010510A (es) Compuestos del inhibidor de raf y métodos de uso de los mismos
NI202100027A (es) Inhibidores de la proteína tirosina fosfatasa
CR11690A (es) Pirazolo (3,4-b) piridinas como inhibidores de raf
UY30112A1 (es) Nuevos benzotiazoles sustitidos por heteroarilo
MX2019005306A (es) Compuestos mono y espirociclicos que continen ciclobutano y azetidina como inhibidores de la integrina alfa v.
UY32810A (es) Compuestos de heteroarilo y sus usos
DOP2019000020A (es) Compuestos de tiazolo-piridina sustituida como inhibidores de malt1
CY1116692T1 (el) Πυρρολοπυριδινες ως αναστολεις κινασης
CU24605B1 (es) Pirimidin-2-il amino-1h-pirazoles útiles como inhibidores de lrrk2
CR20140399A (es) Pirrolidina-2-carboxamidas sustituidas
MX2016008624A (es) Inhibidores de serina/treonina cinasa.
NI201200044A (es) Compuestos de dióxido de iminotiadiazina como inhibodores de bace , composiciones y su uso
NI201000164A (es) Hidroximetil pirrolidinas como agonistas del receptor adrenérgico beta 3.
EA201100136A1 (ru) 2,4'-бипиридинилы в качестве ингибиторов протеинкиназы d, применимые для лечения сердечной недостаточности и рака
MD4820B1 (ro) Compuşi dihidroizochinolinonici substituiţi
AR072012A1 (es) Pirrolidin sulfonamidas aneladas con grupo de cabeza de oxadiazolona, producto farmaceutico que comprende el compuesto activo y una o mas sustancias activas, y procedimiento de preparacion del producto
ECSP13012596A (es) Proceso de elaboración para derivados de pirimidina
EA201290208A1 (ru) Способ лечения андроген-рецептор позитивных раковых заболеваний
UY33238A (es) "Compuestos en calidad de antagonistas de bradiquinina-b1"
EA201890221A1 (ru) Hbed-бисфосфонаты, их конъюгаты с радиометаллом и их применение в качестве лечебно-диагностических агентов
DOP2011000134A (es) Lactamas como inhibidores de beta secretasa
ECSP099722A (es) Compuestos de pirido [2, 3-d] pirimidina-7-ona como inhibidores de pi3k-alfa para el tratamiento del cáncer
CO6341625A2 (es) Derivados de indol como agentes anticáncer
AR114029A2 (es) Compuestos adecuados como precursores de compuestos que son útiles para obtener imágenes de depósitos amiloides, usos y procesos

Legal Events

Date Code Title Description
FB Suspension of granting procedure